Showing 2241-2250 of 7668 results for "".
- AI in Action: Perfect Corp. Debuts New Skin Type Detection Technologyhttps://practicaldermatology.com/news/ai-in-action-perfect-corp-debuts-new-skin-type-detection-technology/2461883/Perfect Corp. is rolling out its new Skin Type Detection technology, powered by AI. The AI Skin Type Detection supports detection across the T-zone and U-zone of the face to determine normal, oily, dry, sensitive, and combination skin types. It also detects various degrees of sensitivity based on…
- First AD Patient Dosed in Lynk Pharmaceuticals' Phase Ib Clinical Study of Topical JAK Inhibitorhttps://practicaldermatology.com/news/first-ad-patient-dosed-in-lynk-pharmaceuticals-phase-ib-clinical-study-of-topical-jak-inhibitor/2461881/The first atopic dermatitis (AD) patient has been dosed in a Phase Ib clinical trial of LNK01004, Lynk Pharmaceuticals Co., Ltd. The trial was designed to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of LNK01004 ointment in Chinese patients with mild…
- ASA’s SPOTS Program Wins an International Award for Social Responsibility in Dermatologyhttps://practicaldermatology.com/news/asas-spots-program-wins-an-international-award-for-social-responsibility-in-dermatology/2461880/The American Skin Association (ASA)’s SPOTS (Sun Protection Outreach Teaching by Students) program was selected as one of five "Top Projects" in North America by the International Awards for Social Responsibility in Dermatology. The awards are a partnership between the World Congress of Dermatolo…
- LRP Celebrates Acne Positivity with Two-Day 'Positivity Lab' Pop-Up Experience in NYChttps://practicaldermatology.com/news/lrp-celebrates-acne-positivity-with-two-day-positivity-lab-pop-up-experience-in-nyc/2461879/La Roche-Posay is hosting a consumer pop-up experience to help destigmatize acne. The pop-up will feature an immersive "Science of Skin" exhibit, a meditation lounge in partnership with obé Fitness, Doodle Bar with custom art done by local artists, and a Positivity Photo Booth – plus, free probiot…
- Azitra Adds Barbara Ryan and John Schroer to Board of Directorshttps://practicaldermatology.com/news/azitra-adds-barbara-ryan-and-john-schroer-to-board-of-directors/2461876/Barbara Ryan and John Schroer joined Azitra, Inc.’s board of directors. "We are thrilled to further strengthen the Azitra team by welcoming Barbara and John to our board and by leveraging their wealth of knowledge in biotech, corporate strategy, and capital markets," says Francisco Salva, Presiden…
- Enspectra Health Awarded NIH Grant to Advance Predictive Algorithms for AKshttps://practicaldermatology.com/news/enspectra-health-awarded-nih-grant-to-advance-predictive-algorithms-for-aks/2461874/Enspectra Health scored $2M in grant funding from the National Cancer Institute (NCI) to support research for developing deep learning algorithms to predict which actinic keratosis (AK) lesions, are likely to progress to squamous cell carcinoma (SCC). Enspectra's technology combines reflectance co…
- Hoth Therapeutics Receives Protocol Approval for HT-001https://practicaldermatology.com/news/hoth-therapeutics-receives-protocol-approval-for-ht-001/2461873/Hoth Therapeutics, Inc. received approval from the Food & Drug Administration (FDA) for a protocol change in its Phase 2a clinical trial of HT-001. Participants will apply HT-001 Gel once per day for six weeks, during which the effect on treating acneiform rash and other skin disorders induced by…
- FDA Clears Xstrahl’s Radiant Aura for NMSCshttps://practicaldermatology.com/news/fda-clears-radiant-aura-receives-us-food-and-drug-administration-fda-510k-clearance/2461871/The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Xstrahl’s Radiant Aura, an office-based radiation therapy for non-melanoma skin cancer (NMSC). “We developed Radiant Aura to deliver both electronic brachytherapy and superficial radiation therapy in order to give dermatol…
- Warts and All: Novan Files Chapter 11, Sells Assetshttps://practicaldermatology.com/news/warts-and-all-novan-files-chapter-11-sells-assets/2461870/Novan is selling all of its assets, including Berdazimer Gel, 10.3% (SB206), and has filed for Chapter 11 Protection. The Company entered into a stalking horse asset purchase agreement (APA) with Ligand Pharmaceuticals, Inc. prior to filing voluntary petitions for relief under chapter 11 of title…
- EMA to Review UCB’s Bimekizumab for HShttps://practicaldermatology.com/news/ema-to-review-ucbs-bimekizumab-for-hs/2461869/The European Medicines Agency (EMA) will reviww UCB’s marketing authorization application for bimekizumab for the treatment of adults with moderate to severe hidradenitis suppurativa (HS). Bimekizumab is an IL-17A and IL-17F inhibitor. The safety and efficacy of bimekizumab in HS have not been est…